{"id":841381,"date":"2025-04-24T07:33:20","date_gmt":"2025-04-24T11:33:20","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-report-first-quarter-2025-financial-results\/"},"modified":"2025-04-24T07:33:20","modified_gmt":"2025-04-24T11:33:20","slug":"kura-oncology-to-report-first-quarter-2025-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-report-first-quarter-2025-financial-results\/","title":{"rendered":"Kura Oncology to Report First Quarter 2025 Financial Results"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">SAN DIEGO, April  24, 2025  (GLOBE NEWSWIRE) &#8212; Kura Oncology, Inc. (the \u201cCompany\u201d) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report first quarter 2025 financial results after the close of U.S. financial markets on Thursday, May 1, 2025. Kura\u2019s management will host a webcast and conference call at 4:30 p.m. ET \/ 1:30 p.m. PT to discuss the financial results and provide a corporate update.<\/p>\n<p align=\"justify\">The live call may be accessed by dialing (800) 245-3047 for domestic callers and (203) 518-9765 for international callers and entering the conference ID: KURAQ1. A live webcast and archived replay of the event will be available <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nLOmhdnMKVt9sINFQ6fGjUHEWly5x3mLI6gZGm_g5ic5B7qcTChDfcOxvJbImgPkK_Ly155g2Q84j3hoa_ZR3kRVmTdn72DW_NdFnkqBf9pS38c_-8oEbV4X_FiaCW_NRaLNEsOBC6ITXRRWgDdX0Q==\" rel=\"nofollow\" target=\"_blank\">here<\/a> or online from the investor relations section of the company website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VnHAB2f55_ZLpbKm7EYJz3Ga34uAYzew7Va6Z4W2fiDUJ616IV9a1khLuY23ott2U-qICslFT4hZCkVs6wRQZ6yEzkNe4ekCuEtFomqpSec=\" rel=\"nofollow\" target=\"_blank\">www.kuraoncology.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About Kura Oncology<\/strong>\n      <\/p>\n<p align=\"justify\">Kura Oncology\u00a0is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company\u2019s pipeline consists of small molecule drug candidates, designed to target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food &amp; Drug Administration for the treatment of relapsed\/refractory (R\/R) <em>NPM1<\/em>-mutant (<em>NPM1<\/em>-m) AML. In\u00a0November 2024, Kura entered into a global strategic collaboration agreement with\u00a0Kyowa Kirin to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R\/R <em>NPM1<\/em>-m AML has been completed, and in the second quarter of 2025, the companies announced submission of an NDA for ziftomenib for the treatment of adult patients with R\/R <em>NPM1<\/em>-m AML. Kura and\u00a0Kyowa Kirin\u00a0are conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R\/R <em>NPM1<\/em>-m and <em>KMT2A<\/em>-rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor (FTI), is being evaluated in a Phase 1 dose-escalation trial (FIT-001) as a monotherapy and in combination with targeted therapies for patients with various solid tumors. Tipifarnib, a potent and selective FTI, is currently in a Phase 1\/2 trial (KURRENT-HN) in combination with alpelisib for patients with <em>PIK3CA<\/em>-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura\u2019s website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kr1cLR8XCTHm5o_2Xnxog8K5GC6UPgyUF3f2lFHpvrYXMg6Ayp3xUPq99bw9qbf8PxRPqxiCvlVha3EbMUptZBwaqVBIYCRrkUe-4rgZWqI=\" rel=\"nofollow\" target=\"_blank\">https:\/\/kuraoncology.com\/<\/a> and follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=M-ZaGnaHaj2gwNT4nPzDHo9Pj0k5UnmrJQCvhw2BKAouckE2WD3jTRrnoQWstoNmQ5xmsoT8iNL1fmQ88cMgMA==\" rel=\"nofollow\" target=\"_blank\">X<\/a>\u00a0and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lq2xc94Paop7GjrTKeME36vQsDTDl35mDdcFv0-6_9g0qVkwb1od9ff9xpNCU2VK4hc1l2AMDr7-d_h2Xs9ZWDIeVFd-PnKfRGlxlJJDPoIuedsiBnL5bPD2a-wDk6df\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p>\n        <strong>Contacts<\/strong>\n      <\/p>\n<p align=\"justify\">Investors:<br \/>Patti Bank<br \/>Managing Director<br \/>(415) 513-1284<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LI60m5qKUQ8YqVGzcYtyIaav5ucrhWXo6bHIr8s1wZcovijd0fYW3r7NpNDWNDLpuxoMrIubfZexi82iLs9nvNIkwtKSL-pE3RMGE1SKXNDBy6ktxiwhIT5KDCkzRAx3\" rel=\"nofollow\" target=\"_blank\">patti.bank@icrhealthcare.com<\/a><\/p>\n<p align=\"justify\">Media:<br \/>Alexandra Weingarten<br \/>Associate Director, Corporate Communications <br \/>&amp; Investor Relations<br \/>(858) 500-8822<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-wzxDo74ICMxsQcTCVGkybzuwVV1QhUwd08TreIkJGQv8-etKIme4vObwaY5c0UPpKGPWfeoZVyPfXfWN_rhhMI4a1Snm8D34uOSpxeYvfDq9LRruHKUBw8JOposjt4r\" rel=\"nofollow\" target=\"_blank\">alexandra@kuraoncology.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzNzUyOCM2OTAxMDcxIzIwMTcxOTU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NTcyYzZmMWYtYjBkYS00MDliLWFjZGItOTk5Y2I3NjUzMDI4LTEwMjg3NjgtMjAyNS0wNC0yNC1lbg==\/tiny\/Kura-Oncology-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) &#8212; Kura Oncology, Inc. (the \u201cCompany\u201d) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report first quarter 2025 financial results after the close of U.S. financial markets on Thursday, May 1, 2025. Kura\u2019s management will host a webcast and conference call at 4:30 p.m. ET \/ 1:30 p.m. PT to discuss the financial results and provide a corporate update. The live call may be accessed by dialing (800) 245-3047 for domestic callers and (203) 518-9765 for international callers and entering the conference ID: KURAQ1. A live webcast and archived replay of the event will be available here or &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-report-first-quarter-2025-financial-results\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Kura Oncology to Report First Quarter 2025 Financial Results&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-841381","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Kura Oncology to Report First Quarter 2025 Financial Results - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-report-first-quarter-2025-financial-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kura Oncology to Report First Quarter 2025 Financial Results - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) &#8212; Kura Oncology, Inc. (the \u201cCompany\u201d) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report first quarter 2025 financial results after the close of U.S. financial markets on Thursday, May 1, 2025. Kura\u2019s management will host a webcast and conference call at 4:30 p.m. ET \/ 1:30 p.m. PT to discuss the financial results and provide a corporate update. The live call may be accessed by dialing (800) 245-3047 for domestic callers and (203) 518-9765 for international callers and entering the conference ID: KURAQ1. A live webcast and archived replay of the event will be available here or &hellip; Continue reading &quot;Kura Oncology to Report First Quarter 2025 Financial Results&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-report-first-quarter-2025-financial-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-24T11:33:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzNzUyOCM2OTAxMDcxIzIwMTcxOTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kura-oncology-to-report-first-quarter-2025-financial-results\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kura-oncology-to-report-first-quarter-2025-financial-results\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Kura Oncology to Report First Quarter 2025 Financial Results\",\"datePublished\":\"2025-04-24T11:33:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kura-oncology-to-report-first-quarter-2025-financial-results\\\/\"},\"wordCount\":416,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kura-oncology-to-report-first-quarter-2025-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQzNzUyOCM2OTAxMDcxIzIwMTcxOTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kura-oncology-to-report-first-quarter-2025-financial-results\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kura-oncology-to-report-first-quarter-2025-financial-results\\\/\",\"name\":\"Kura Oncology to Report First Quarter 2025 Financial Results - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kura-oncology-to-report-first-quarter-2025-financial-results\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kura-oncology-to-report-first-quarter-2025-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQzNzUyOCM2OTAxMDcxIzIwMTcxOTU=\",\"datePublished\":\"2025-04-24T11:33:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kura-oncology-to-report-first-quarter-2025-financial-results\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kura-oncology-to-report-first-quarter-2025-financial-results\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kura-oncology-to-report-first-quarter-2025-financial-results\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQzNzUyOCM2OTAxMDcxIzIwMTcxOTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQzNzUyOCM2OTAxMDcxIzIwMTcxOTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kura-oncology-to-report-first-quarter-2025-financial-results\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kura Oncology to Report First Quarter 2025 Financial Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kura Oncology to Report First Quarter 2025 Financial Results - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-report-first-quarter-2025-financial-results\/","og_locale":"en_US","og_type":"article","og_title":"Kura Oncology to Report First Quarter 2025 Financial Results - Market Newsdesk","og_description":"SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) &#8212; Kura Oncology, Inc. (the \u201cCompany\u201d) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report first quarter 2025 financial results after the close of U.S. financial markets on Thursday, May 1, 2025. Kura\u2019s management will host a webcast and conference call at 4:30 p.m. ET \/ 1:30 p.m. PT to discuss the financial results and provide a corporate update. The live call may be accessed by dialing (800) 245-3047 for domestic callers and (203) 518-9765 for international callers and entering the conference ID: KURAQ1. A live webcast and archived replay of the event will be available here or &hellip; Continue reading \"Kura Oncology to Report First Quarter 2025 Financial Results\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-report-first-quarter-2025-financial-results\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-24T11:33:20+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzNzUyOCM2OTAxMDcxIzIwMTcxOTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-report-first-quarter-2025-financial-results\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-report-first-quarter-2025-financial-results\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Kura Oncology to Report First Quarter 2025 Financial Results","datePublished":"2025-04-24T11:33:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-report-first-quarter-2025-financial-results\/"},"wordCount":416,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-report-first-quarter-2025-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzNzUyOCM2OTAxMDcxIzIwMTcxOTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-report-first-quarter-2025-financial-results\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-report-first-quarter-2025-financial-results\/","name":"Kura Oncology to Report First Quarter 2025 Financial Results - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-report-first-quarter-2025-financial-results\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-report-first-quarter-2025-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzNzUyOCM2OTAxMDcxIzIwMTcxOTU=","datePublished":"2025-04-24T11:33:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-report-first-quarter-2025-financial-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-report-first-quarter-2025-financial-results\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-report-first-quarter-2025-financial-results\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzNzUyOCM2OTAxMDcxIzIwMTcxOTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzNzUyOCM2OTAxMDcxIzIwMTcxOTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-report-first-quarter-2025-financial-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Kura Oncology to Report First Quarter 2025 Financial Results"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/841381","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=841381"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/841381\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=841381"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=841381"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=841381"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}